In contrast, phase I trials with the second-generation ALK inhibitor, ceritinib, showed clinically relevant responses in a fraction of patients with refractory or relapsed neuroblastoma, but the response duration was short, indicating early resistance development [32]. The gene discussed is ALK; the disease is neuroblastoma.